Mutationof the L1CAM gene (Xq28) is characterized by hydrocephalus, mentalretardation, spasticity of the legs, and adducted thumbs. The phenotypicspectrum of L1CAM mutations includes X-linked hydrocephalus with stenosisof the aqueduct of Sylvius (HSAS), MASA syndrome (mental retardation, aphasia(delayed speech), spastic paraplegia (shuffling gait), adducted thumbs), SPG1(X-linked complicated hereditary spastic paraplegia type 1), and X-linkedcomplicated corpus callosum agenesis. The group of conditions as a whole can bereferred to as L1 syndrome.
Hydrocephalusin L1 syndrome may be present prenatally and result in stillbirth or death inearly infancy. Males with HSAS are born with severe hydrocephalus and adductedthumbs. Seizures may occur. In less severely affected males, hydrocephalus maybe subclinically present and documented only because of developmental delay.Mild-to-moderate ventricular enlargement is compatible with long survival.Mental retardation is usually severe and is independent of shunting proceduresin individuals with severe hydrocephalus. In MASA syndrome, mental retardationranges from mild (IQ of 50-70) to moderate (IQ of 30-50). The degree ofintellectual impairment does not necessarily correlate with head size orseverity of hydrocephalus; males with severe mental retardation and a normalhead circumference have been reported. All phenotypes can be observed inaffected individuals in the same family. Females may manifest minor featuressuch as adducted thumbs and/or subnormal intelligence. Rarely do femalesmanifest the complete L1 syndrome phenotype.
X-linkedhydrocephalus with stenosis of the aqueduct of Sylvius is the most commongenetic form of congenital hydrocephalus, with a prevalence of approximatelyone in 30,000. This accounts for approximately 5%-10% of males withnonsyndromic congenital hydrocephalus.
Whilemutation detection rates are unknown, point mutations, partial gene deletions,and partial gene duplications have all been reported. Although uncommon, denovo disease-causing mutations have been reported.
For patients with a suspected L1CAM-related disorder, sequence analysis is recommended as the first step in mutation identification. For patients in whom mutations are not identified by full gene sequencing, deletion/duplication analysis is appropriate.
Click here for the GeneTests summary on this condition.
This test is indicated for:
- Confirmation of a clinical diagnosis of L1 syndrome
- Carrier testing in adult females with a family history of L1 syndrome
Clinical Sensitivity: Unknown. Mutations in the promoter region, some mutations in the introns and other regulatory element mutations cannot be detected by this analysis. Large deletions will not be detected by this analysis. Results of molecular analysis should be interpreted in the context of the patient's biochemical phenotype.
Analytical Sensitivity: ~99%
Infants and Young Children (<2 years of age): 2-3 ml
Children > 2 years of age to 10 years old: 3-5 ml
Older Children & Adults: 5-10 ml
Autopsy: 2-3 ml unclotted cord or cardiac blood
Isolation using the Perkin Elmer™Chemagen™ Chemagen™ Automated Extraction method or Qiagen™ Puregene kit for DNA extraction is recommended.
Orangene™ Saliva Collection Kit used according to manufacturer instructions. Please contact EGL for a Saliva Collection Kit for patients that cannot provide a blood sample.
Submit copies of diagnostic biochemical test results with the sample, if appropriate. Contact the laboratory if further information is needed.
Sequence analysis is required before deletion/duplication analysis by targeted CGH array. If sequencing is performed outside of EGL Genetics, please submit a copy of the sequencing report with the test requisition.
- Deletion/duplication analysis of the L1CAM gene by CGH array is available for those individuals in whom sequence analysis is negative.
- A CGH array-based test for deletion/duplication analysis of 109 different X-linked intellectual disability genes is available.
- Custom diagnostic mutation analysis is available to family members if mutations are identified by targeted mutation testing or sequencing analysis.
- Prenatal testing is available to adult females who are confirmed carriers of mutations. Please contact the laboratory genetic counselor to discuss appropriate testing prior to collecting a prenatal specimen.